Lead Product(s): Hyaluronic Acid
Therapeutic Area: Dermatology Product Name: Hyaluronic Acid Filler Princess
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: China National Biotech Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 15, 2020
The joint venture comprises Croma's Hyaluronic Acid Filler Princess® VOLUME and additional filler and facial aesthetic products and CNBG's multi-channel distribution, marketing experience and synergistic products, specifically its botulinum toxin product Heng Li®.
Lead Product(s): Botulinum toxin type A
Therapeutic Area: Dermatology Product Name: BoNT/A-DP
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2020
Croma’s botulinum toxin submission in Europe is based on 2 completed randomized, placebo-controlled Phase III pivotal trials (BLESS I and II) that enrolled a total of 917 subjects in Europe and the US.